Amneal Pharmaceuticals highlighted positive study results from Kashiv BioSciences and is currently seeking FDA approval for a biosimilar product.
2 reports, 1 independent
Updated Jul 17
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Amneal Pharmaceuticals highlighted positive study results from Kashiv BioSciences and is currently seeking FDA approval for a biosimilar product.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Amneal Pharmaceuticals acquired Kashiv BioSciences, a move Chirag Patel called pivotal for creating an end-to-end biosimilar presence.Sub-event
Amneal Pharmaceuticals gained approvals in the U.S. market for its biosimilar product.1 source
- Amneal seeks FDA approval for biosimilar based on Kashiv study results.
Keep exploring
The entities involved
-
Amneal Pharmaceuticals, Inc.
American publicly traded generics and specialty pharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- manilatimes.net
- Unknown outlet